

For immediate release

ZOOMMED ANNOUNCES THAT THE TSX VENTURE EXCHANGE HAS CONDITIONALLY APPROVED ITS QUALIFYING TRANSACTION

Montreal, July 18, 2005 – ZoomMed inc. (« ZoomMed »), a capital pool corporation (TSX Venture Exchange: ZMD.P), is proud to announce that the TSX Venture Exchange has conditionally approved the qualifying transaction resulting from the agreement in principle entered into on May 26, 2005 (the "Agreement in Principle") providing for the acquisition of all the issued and outstanding common shares of 9103-8240 Québec inc. (the « Target Company »), which in turn holds all the issued and outstanding shares of 4130936 Canada Inc. (collectively, the "Businesses"). This share purchase will be made in consideration of a price of \$4,500,000, payable by the issuance of 18,000,000 common shares of ZoomMed, at a price of \$0.25 per share.

ZoomMed proceeded today with the filing of its filing statement, through SEDAR, in accordanc with the applicable policies of the TSX Venture Exchange. This filing statement is therefore available to the public through SEDAR.

ZoomMed intends to proceed to close its qualifying transaction described in its filing statement, 7 business days following the date of this press release, that is to say next 27 July, 2005, as required by the applicable policies of the TSX Venture Exchange.

The Businesses are specialized in the reinstatement, management and restoration of pre-used or, if needed, new medical and laboratory equipment, and also offers as a complement, replacement parts. In this respect, the Businesses purchase used equipment, see to its restoration, and finally, resell such equipment in the market.

The board of directors of **ZoomMed** have approved the adoption of a stock option plan in respect of 10% of the issued and outstanding common shares following the completion of the qualifying transaction mentioned above, the coming into force of which remains subject to the approval of the TSX Venture Exchange and the "Autorité des marches financiers du Québec".

The TSX Venture Exchange has neither approved nor accepts any responsibility with respect to the veracity or exactitude of this press release.

Information: Valier Boivin, Director ZoomMed inc. (514) 844-5468